Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,751 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,318)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05042336 | The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC | unknown | Phase 1 / Phase 2 | 49 | Sichuan UniversityOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT04331743 | A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jun 16, 2021 | clinicaltrials |
| NCT04926532 | Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma(Toripalimab) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04843943 | Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Apr 14, 2021 | clinicaltrials |
| NCT04121273 | GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC | unknown | Phase 1 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04170595 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection | unknown | Phase 1 / Phase 2 | 132 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04750382 | A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 31 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 11, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03703063 | Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | unknown | Phase 1 | 30 | Benaroya Research InstituteOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04665362 | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | unknown | Phase 1 | 10 | Liang PengOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04677088 | TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation | unknown | Phase 1 | 7 | Xiaoshun HeOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | unknown | Phase 1 | 10 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04104074 | Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis | unknown | Phase 1 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04380103 | A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 106 | Chinese Academy of Medical SciencesOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT04368182 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 3 | Zhejiang UniversityOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT03971747 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 9 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 39 | Henan Cancer HospitalOTHER_GOV | 0 | Dec 30, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03855358 | A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) | unknown | Phase 1 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT04107142 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | unknown | Phase 1 | 10 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT03993743 | A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 34 | Xijing HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT04032392 | Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells | unknown | Phase 1 | 20 | Beijing 302 HospitalOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT03966209 | Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03899415 | TCR-Redirected T Cells Therapy in Patient With HBV Related HCC | unknown | Phase 1 | 10 | Beijing 302 HospitalOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03908840 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 12 | Evolve BiologicsINDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT03881878 | TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery | unknown | Phase 1 / Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01295502 | Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer | unknown | Phase 1 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03793322 | The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma | unknown | Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT02719782 | A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation | unknown | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT02293850 | Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Oncolys BioPharma IncINDUSTRY | 2 | Aug 20, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 13, 2021source: clinicaltrials